FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:312-317 January 23, 2003 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In patients with amenorrhea and infertility, increased levels of serum luteinizing hormone and follicle-stimulating hormone are usually due to primary gonadal failure, whereas a selective increase in luteinizing hormone can be seen with polycystic ovary syndrome. By contrast, an isolated elevation in luteinizing hormone above the postmenopausal range is uncommon and prompts evaluation of the luteinizing hormone assay. The luteinizing hormone value may be spuriously elevated if human chorionic gonadotropin levels are increased and assay antibodies recognize both hormones. In addition, circulating heterophilic antibodies may interact in an assay, causing an apparent elevation of luteinizing hormone.¹

A verified abnormal result . . . [Full Text of this Article]

Case Report

Methods

Clinical Protocol

Immunohistochemical Evaluation of Tumor

Results

Laboratory Tests and Imaging

Pathological Evaluation

Recovery of the Hypothalamic–Pituitary–Ovarian Axis

Discussion

Source Information

From the Transplantation and Autoimmunity Branch, National Institute of Diabetes and Digestive and Kidney Diseases (B.H.), the Developmental Endocrinology Branch (G.I.U.), and the Pediatric and Reproductive Endocrinology Branch (L.K.N.), National Institute of Child Health and Human Development, and the Laboratory of Pathology, National Cancer Institute (B.D.C.), National Institutes of Health, Bethesda, Md.; the Oregon Health and Science University, Beaverton (P.M.C.); and the Genetics and IVF Institute, Fairfax, Va. (K.L.B.).

Address reprint requests to Dr. Nieman at Bldg. 10, Rm. 9D42, 10 Center Dr., MSC 1583, Bethesda, MD 20892-1583, or at niemanl@nih.gov.

This article has been cited by other articles:

• Piaditis, G., Angellou, A., Kontogeorgos, G., Mazarakis, N., Kounadi, T., Kaltsas, G., Vamvakidis, K., Lloyd, R. V., Horvath, E., Kovacs, K. (2005). Ectopic Bioactive Luteinizing Hormone Secretion by a Pancreatic Endocrine Tumor, Manifested as Luteinized Granulosa-Thecal Cell Tumor of the Ovaries. J. Clin. Endocrinol. Metab. 90: 2097-2103 [Abstract] [Full Text]  
• Miehle, K., Tannapfel, A., Lamesch, P., Borte, G., Schenker, E., Kluge, R., Ott, R. A., Wiechmann, V., Koch, M., Kassahun, W., Paschke, R., Koch, C. A. (2004). Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropin Production upon Second Recurrence. J. Clin. Endocrinol. Metab. 89: 3731-3736 [Abstract] [Full Text]  
• Kaltsas, G. A., Besser, G. M., Grossman, A. B. (2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev. 25: 458-511 [Abstract] [Full Text]